No Data
No Data
TLSA: 1H:21 Financial Update
Tianyan Pharmaceutical Announces Financial Results and Company Progress for the First Half of 2021
- Three clinical collaborations were reached with Mercadon to advance the global joint trial of three clinical antitumor candidates and pavolizumab -- ADG106 monopharmaceutical clinical trials showed efficacy and safety; focused on promoting indications with high biomarker expression and combined treatment targeting PD-1 resistant patients- - Ongoing phase I trials showed a novel anti-CTLA-4 novel epitopic antibody (NeoBodyTM) ADG116 with highly differentiated clinical product characterization -- First safe antibody project ADG126 I Phase clinical dosage climbed smoothly
12 Health Care Stocks Moving In Wednesday's After-Market Session
PDL BioPharma shares are trading higher after Silver Point Capital disclosed the purchase of 1.565 million shares.
PDL Biopharma 10%+ Owner Edward Mule Reported Purchase of 1,565,000 Shares @ Avg Price of $2.60/Share in Form 4 Filing on Wednesday
PDL Biopharma 10%+ Owner Edward Mule Reported Purchase of 2,090,000 Shares @ Avg Price of $2.57/Share in Form 4 Filing on Tuesday
No Data
No Data